Overview

A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

This was a Phase IV multicenter, randomized, open-label study, with masking of the vision examiner, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).

Phase:

Phase 4

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Ranibizumab